Misplaced Pages

Nepadutant

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Nepadutant
Clinical data
Routes of
administration		Injection
ATC code
  • None
Pharmacokinetic data
Bioavailability<3% (oral)
Elimination half-life44 minutes (IV)
Identifiers
IUPAC name
  • (2S)-2-amino]-2-amino-4-oxobutanoyl]amino]-6-benzyl-9-(1H-indol-3-ylmethyl)-5,8,11,14-tetraoxo-1,4,7,10-tetrazacyclotetradecane-3-carbonyl]amino]-4-methylpentanoic acid
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
Chemical and physical data
FormulaC45H60N10O14
Molar mass965.031 g·mol
3D model (JSmol)
SMILES
  • CC(C)C(C(=O)O)NC(=O)1CNC(=O)C(C(=O)N(C(=O)N(C(=O)N1)Cc2ccccc2)Cc3cc4c3cccc4)NC(=O)(CC(=O)N5((((O5)CO)O)O)NC(=O)C)N
InChI
  • InChI=1S/C45H60N10O14/c1-21(2)13-31(45(67)68)53-43(66)32-19-48-34(58)17-30(50-39(62)26(46)16-35(59)55-44-36(49-22(3)57)38(61)37(60)33(20-56)69-44)42(65)52-29(15-24-18-47-27-12-8-7-11-25(24)27)41(64)51-28(40(63)54-32)14-23-9-5-4-6-10-23/h4-12,18,21,26,28-33,36-38,44,47,56,60-61H,13-17,19-20,46H2,1-3H3,(H,48,58)(H,49,57)(H,50,62)(H,51,64)(H,52,65)(H,53,66)(H,54,63)(H,55,59)(H,67,68)/t26-,28-,29-,30-,31-,32-,33+,36+,37+,38+,44+/m0/s1
  • Key:NPSVXOVMLVOMDD-SXRVEDALSA-N

Nepadutant (INN) (code name MEN-11420) is a glycosylated bicyclic cyclohexapeptide drug which acts as a highly selective NK2 receptor antagonist. It was developed by the Menarini Group and investigated for the treatment of functional gastrointestinal disorders and asthma but was never marketed.

See also

References

  1. ^ Annual Reports in Medicinal Chemistry. Academic Press. 8 September 1999. pp. 56–. ISBN 978-0-08-058378-5.
  2. ^ Holzer P (17 June 2004). Tachykinins. Springer. pp. 224–226. ISBN 978-3-540-20690-3.
  3. ^ Regitz-Zagrosek V (2 October 2012). Sex and Gender Differences in Pharmacology. Springer Science & Business Media. pp. 489–. ISBN 978-3-642-30726-3.
  4. Royal Society of Chemistry (Great Britain) (January 2003). Amino Acids, Peptides and Proteins. Royal Society of Chemistry. ISBN 978-0-85404-242-5.
  5. Frank B (29 June 2011). Women's Issues in Gastroenterology, An Issue of Gastroenterology Clinics. Elsevier Health Sciences. pp. 54–55. ISBN 978-1-4557-1220-5.
  6. Jancso G (27 November 2008). Neurogenic Inflammation in Health and Disease. Elsevier. pp. 297–. ISBN 978-0-444-53229-9.


Drugs for functional gastrointestinal disorders (A03)
Drugs for
functional
bowel
disorders
Antimuscarinics
Tertiary
amino group
Quaternary
ammonium
compounds
Phosphodiesterase
inhibitors
Acting on
serotonin receptors
Other
Belladonna
and derivatives
(antimuscarinics)
Propulsives
Drugs for obstructive airway diseases: asthma/COPD (R03)
Adrenergics, inhalants
Short-acting β2 agonists
Long-acting β2 agonists
Ultra-long-acting β2 agonists
Other
Glucocorticoids
Anticholinergics/
muscarinic antagonist
Mast cell stabilizers
Xanthines
Eicosanoid inhibition
Leukotriene antagonists
Arachidonate 5-lipoxygenase inhibitors
Thromboxane receptor antagonists
Non-xanthine PDE4 inhibitors
Others/unknown
Combination products
Neurokinin receptor modulators
NK1
NK2
NK3
Tryptamines
Tryptamines
N-Acetyltryptamines
α-Alkyltryptamines
Triptans
Cyclized tryptamines
Isotryptamines
Related compounds


Stub icon

This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it.

Categories: